Clinical trials: IgG4-Related Diseases
IgG4-related Disease
Tofatib Treatment for IgG4-related Disease
Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.
- Trial name
- NCT05625581
- Testing
- tofacitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changhai Hospital
IgG4-related Disease
A Prospective Cohort Study of IgG4RD in China
This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.
- Trial name
- NCT01670695
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
IgG4 Related Disease
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).
- Trial name
- NCT04540497
- Testing
- Inebilizumab
- Where
- 72 sites in United States, Argentina and 19 more
- Volunteers
- 135 people
- Sponsor
- Amgen
IgG4-Related Disease
A Study of IMM0306 in IgG4-Related Disease
The goal of this clinical trial is to learn if IMM0306 works to reduce the risk of disease relapse in participants with IgG4-related disease (IgG4-RD). It will also learn about the safety and tolerability of IMM0306.
- Trial name
- NCT07621939
- Testing
- IMM0306
- Volunteers
- 125 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
IgG4 Related Disease, Covid19
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
Since December 2019, coronavirus disease 2019 (COVID-19), caused by the severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than 124 million people worldwide as of 23/3/2021.
- Trial name
- IgG4-COVID (NCT04817553)
- Testing
- exposure to COVID19
- Where
- Hong Kong
- Volunteers
- 124 people
- Sponsor
- Chinese University of Hong Kong
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497387
- Testing
- PRG-1801
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
IgG4 Related Disease
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
Enquire involvement of trained immunity in the pathogenesis of IgG4RD
- Trial name
- TRIM4 (NCT06844864)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
IgG4-related Disease
A Study of Efgartigimod in Patients With IgG4-Related Disease
The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are: In patients with IgG4-related disease, does treatment with efgartigimod reduce the…
- Trial name
- NCT07025330
- Testing
- Efgartigimod
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis
Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids
This study evaluates corticosteroids in the treatment of obstructive jaundice in autoimmune pancreatitis and/or immunoglobulin G4 (IgG4)-related sclerosing cholangitis in adults.
- Conditions
- Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis, Obstructive Jaundice
- Trial name
- NCT02797665
- Testing
- corticosteroids, biliary stent
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Immunoglobulin G4 Related Disease
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD).
- Trial name
- NCT04520451
- Testing
- rilzabrutinib, Glucocorticoids
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
- Conditions
- Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
- Trial name
- NCT06978738
- Testing
- universal allogeneic anti-CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changzhou No.2 People's Hospital
Immunoglobulin G4-Related Disease
Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
Immunoglobulin G4-related disease (IgG4-RD) is a chronic immune-mediated disorder characterized by inflammation, fibrosis, and involvement of multiple organs.
- Trial name
- LENITY (NCT07719543)
- Testing
- Lenalidomide
- Where
- 3 sites in China
- Volunteers
- 146 people
- Sponsor
- Chinese PLA General Hospital
Rheumatoid Arthritis, Lupus Erythematosus, Systemic
Meir Medical Center Rheumatologic Biobank
Serum, synovial fluid and skin biopsies from patients will be collected to the biobank with rheumatoid diseases. These samples will later be used for clinical and basic research, following approval of each specific study by the…
- Conditions
- Rheumatoid Arthritis, Lupus Erythematosus, Systemic, Systemic Sclerosis, IgG4-related Disease
- Trial name
- NCT03473912
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Meir Medical Center
IgG4-related Disease
Glucocorticoids in Patients With IgG4-RD
This is a randomized, open-label, single-center clinical trial to compare the efficacy and safety profile for medium-dose versus high dose glucocorticoid in patients with IgG4-related Disease.
- Trial name
- NCT01758393
- Testing
- Prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Autoimmune Diseases
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with superficial organ involvement…
- Trial name
- NCT05789030
- Testing
- glucocorticoid plus iguratimod, glucocorticoid plus leflunomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Autoimmune Disease
Leflunomide Treatment for IgG4-RD
This study is an open-label randomized controlled trial aiming to investigate whether the efficacy and side effect of Leflunpomide plus glucocorticoid.
- Trial name
- NCT03715699
- Testing
- Prednisone, Prednisone and Leflunomide
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Behcet's Disease, Idiopathic Inflammatory Myopathies
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations.
- Conditions
- Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
- Trial name
- DRIMID (NCT06285539)
- Testing
- Filgotinib
- Where
- 6 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- UMC Utrecht
IgG4-related Disease With Eosinophilia
Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
Evaluation of efficacy and safety of Baricitinib combined with glucocorticoid in patients of IgG4-related disease with eosinophilia.
- Trial name
- NCT05781516
- Testing
- Prednisolone, Baricitinib
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Wen Zhang
Plasmablast/Plasma Cells in Diagnosis of IgG4-RD, Plasmablast/Plasma Cells in Relapse Prediction of IgG4-RD
Circulating Plasmablast in Diagnosis and Relapse Prediction of IgG4-RD
300 IgG4-RD patients, 200 other autoimmune diseases, 60 IgG4-RD mimickers and 100 healthy controls were enrolled. Circulating plasmablast/plasma cells were detected of all patients at baseline and healthy controls.
- Trial name
- NCT04539197
- Where
- China
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
IgG4-related Disease
Safety and Efficacy of Abatacept in IgG4-Related Disease
This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study.
- Trial name
- NCT03669861
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital